The White House, FDA, and CDC are evidently not on the same page on COVID-19 booster shots
The Biden administration has been preparing to roll out COVID-19 booster shots on Sept. 20 for most fully immunized adults, assuming the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) agree. The FDA will weigh the evidence for a Pfizer-BioNTech booster shot at a public meeting on Friday, but internal tensions between the FDA, White House, and CDC are already spilling into the open.
Everyone agrees the level of antibodies from the vaccines wanes over time, but there is disagreement over whether approving a third shot is necessary right now, given the other layers of protection from the vaccines and the mildness of most breakthrough infections. Several countries have already approved booster shots for the general population, and Israel is preparing to offer some people a fourth shot.
But in the U.S., the White House COVID-19 task force and FDA "have repeatedly accused CDC of withholding critical data needed to develop the booster shot plan," Politico reports. Some CDC officials view the White House timeline on booster approval as unrealistic.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The "FDA's frustrations with CDC are longstanding and predate the pandemic," Politico notes, but the two agencies are "trying to align" better, especially after the departure of two top FDA vaccine regulators, Marion Gruber and Philip Krause. "The pair announced their retirements this month, in a move that one former official attributed to frustrations with CDC's role in the booster plan."
But Krause and Gruber were among a group of international scientists who argued in British journal The Lancet on Monday that it is premature to offer everyone booster shots.
Universal booster shots may be needed eventually, the Lancet group wrote, but right now other parts of the immune system revved up by the vaccines, like T-cells and memory B cells, are providing really robust protection even as antibody levels decline. They also suggested there could be adverse reactions from repeated vaccinations, and argued that vaccines would be better used to immunize people around the world with no access.
Georgetown University's Larry Gostin said the Lancet paper "throws gasoline on the fire" in the booster shot debate, but the FDA shrugged it off. "We are in the middle of a deliberative process of reviewing Pfizer's booster shot supplemental approval submission," the FDA said, and "as noted in the article, the views of the authors do not represent the views of the agency."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
5 sunny-side up cartoons about egg prices
Cartoons Artists take on inflated prices, double standards, and more
By The Week US Published
-
'Swimming in the sky' in northern Brazil
The Week Recommends The pools of Lençóis Maranhenses are clear and blue
By The Week UK Published
-
An ailing Pope Francis – and the vultures circling in the Vatican
Talking Point Caught between his progressive inner circle and an influx of conservatism, the Holy Father should 'brace' himself for a battle
By The Week UK Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published